Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china

• Main Authors: You, R., Liu, J., Wu, D.B.-C., Qian, X., Lyu, B., Zhang, Y., Luo, N.
• Other Authors: SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
• Format: Article
• Published: Dove Medical Press Ltd 2021
• Subjects: Afatinib; Economic analysis; EGER mutation testing; Incremental cost-effectiveness ratio; NSCLC
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/210062
• Institution: National University of Singapore

10.2147/CMAR.S219722